# A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors

> **NCT04158583** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 76 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RO7296682

## Key facts

- **NCT ID:** NCT04158583
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-09
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-07-21
- **Target enrollment:** 76 (ACTUAL)
- **Why stopped:** Halted in order to focus on the ongoing combination of RO7296682 with Atezolizumab, evaluated in study BP42595, as a higher likelihood for efficacy is expected in combination with Atezolizumab as compared to the monotherapy setting.
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158583, "A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04158583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*